Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Connection

Teresita Bellido to Humans

This is a "connection" page, showing publications Teresita Bellido has written about Humans.

 
Connection Strength
 
 
 
0.683
 
  1. Marino S, Bellido T. PTH receptor signalling, osteocytes and bone disease induced by diabetes mellitus. Nat Rev Endocrinol. 2024 Nov; 20(11):661-672.
    View in: PubMed
    Score: 0.040
  2. Bellido T. Bisphosphonates for osteoporosis: from bench to clinic. J Clin Invest. 2024 Mar 15; 134(6).
    View in: PubMed
    Score: 0.039
  3. Marino S, Ozgurel SU, McAndrews K, Cregor M, Villase?or A, Mamani-Huanca M, Barbas C, Gortazar A, Sato AY, Bellido T. Abaloparatide is more potent than teriparatide in restoring bone mass and strength in type 1 diabetic male mice. Bone. 2024 Apr; 181:117042.
    View in: PubMed
    Score: 0.039
  4. Delgado-Calle J, Bellido T. The osteocyte as a signaling cell. Physiol Rev. 2022 01 01; 102(1):379-410.
    View in: PubMed
    Score: 0.033
  5. Sato AY, Pellegrini GG, Cregor M, McAndrews K, Choi RB, Maiz M, Johnson O, McCabe LD, McCabe GP, Ferruzzi MG, Lila MA, Peacock M, Burr DB, Nakatsu CH, Weaver CM, Bellido T. Skeletal Protection and Promotion of Microbiome Diversity by Dietary Boosting of the Endogenous Antioxidant Response. J Bone Miner Res. 2021 04; 36(4):768-778.
    View in: PubMed
    Score: 0.031
  6. Delgado-Calle J, Sato AY, Bellido T. Role and mechanism of action of sclerostin in bone. Bone. 2017 03; 96:29-37.
    View in: PubMed
    Score: 0.023
  7. Plotkin LI, Bellido T. Osteocytic signalling pathways as therapeutic targets for bone fragility. Nat Rev Endocrinol. 2016 Oct; 12(10):593-605.
    View in: PubMed
    Score: 0.023
  8. Delgado-Calle J, Anderson J, Cregor MD, Hiasa M, Chirgwin JM, Carlesso N, Yoneda T, Mohammad KS, Plotkin LI, Roodman GD, Bellido T. Bidirectional Notch Signaling and Osteocyte-Derived Factors in the Bone Marrow Microenvironment Promote Tumor Cell Proliferation and Bone Destruction in Multiple Myeloma. Cancer Res. 2016 Mar 01; 76(5):1089-100.
    View in: PubMed
    Score: 0.022
  9. Plotkin LI, Bellido T. Comment on Osteocytes: masters orchestrators of bone. Calcif Tissue Int. 2014 Oct; 95(4):382-3.
    View in: PubMed
    Score: 0.020
  10. Ben-awadh AN, Delgado-Calle J, Tu X, Kuhlenschmidt K, Allen MR, Plotkin LI, Bellido T. Parathyroid hormone receptor signaling induces bone resorption in the adult skeleton by directly regulating the RANKL gene in osteocytes. Endocrinology. 2014 Aug; 155(8):2797-809.
    View in: PubMed
    Score: 0.020
  11. Bellido T. Osteocyte-driven bone remodeling. Calcif Tissue Int. 2014 Jan; 94(1):25-34.
    View in: PubMed
    Score: 0.019
  12. Plotkin LI, Bellido T. Beyond gap junctions: Connexin43 and bone cell signaling. Bone. 2013 Jan; 52(1):157-66.
    View in: PubMed
    Score: 0.018
  13. Bellido T, Saini V, Pajevic PD. Effects of PTH on osteocyte function. Bone. 2013 Jun; 54(2):250-7.
    View in: PubMed
    Score: 0.018
  14. Calvi LM, Bromberg O, Rhee Y, Weber JM, Smith JN, Basil MJ, Frisch BJ, Bellido T. Osteoblastic expansion induced by parathyroid hormone receptor signaling in murine osteocytes is not sufficient to increase hematopoietic stem cells. Blood. 2012 Mar 15; 119(11):2489-99.
    View in: PubMed
    Score: 0.017
  15. Tu X, Rhee Y, Condon KW, Bivi N, Allen MR, Dwyer D, Stolina M, Turner CH, Robling AG, Plotkin LI, Bellido T. Sost downregulation and local Wnt signaling are required for the osteogenic response to mechanical loading. Bone. 2012 Jan; 50(1):209-17.
    View in: PubMed
    Score: 0.017
  16. Bellido T. Antagonistic interplay between mechanical forces and glucocorticoids in bone: a tale of kinases. J Cell Biochem. 2010 Sep 01; 111(1):1-6.
    View in: PubMed
    Score: 0.015
  17. Bellido T, Plotkin LI. Novel actions of bisphosphonates in bone: preservation of osteoblast and osteocyte viability. Bone. 2011 Jul; 49(1):50-5.
    View in: PubMed
    Score: 0.015
  18. Plotkin LI, Lezcano V, Thostenson J, Weinstein RS, Manolagas SC, Bellido T. Connexin 43 is required for the anti-apoptotic effect of bisphosphonates on osteocytes and osteoblasts in vivo. J Bone Miner Res. 2008 Nov; 23(11):1712-21.
    View in: PubMed
    Score: 0.014
  19. O'Brien CA, Plotkin LI, Galli C, Goellner JJ, Gortazar AR, Allen MR, Robling AG, Bouxsein M, Schipani E, Turner CH, Jilka RL, Weinstein RS, Manolagas SC, Bellido T. Control of bone mass and remodeling by PTH receptor signaling in osteocytes. PLoS One. 2008 Aug 13; 3(8):e2942.
    View in: PubMed
    Score: 0.013
  20. Aguirre JI, Plotkin LI, Gortazar AR, Millan MM, O'Brien CA, Manolagas SC, Bellido T. A novel ligand-independent function of the estrogen receptor is essential for osteocyte and osteoblast mechanotransduction. J Biol Chem. 2007 Aug 31; 282(35):25501-8.
    View in: PubMed
    Score: 0.012
  21. Plotkin LI, Manolagas SC, Bellido T. Dissociation of the pro-apoptotic effects of bisphosphonates on osteoclasts from their anti-apoptotic effects on osteoblasts/osteocytes with novel analogs. Bone. 2006 Sep; 39(3):443-52.
    View in: PubMed
    Score: 0.011
  22. Bellido T, Ali AA, Gubrij I, Plotkin LI, Fu Q, O'Brien CA, Manolagas SC, Jilka RL. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology. 2005 Nov; 146(11):4577-83.
    View in: PubMed
    Score: 0.011
  23. Manolagas SC, Kousteni S, Chen JR, Schuller M, Plotkin L, Bellido T. Kinase-mediated transcription, activators of nongenotropic estrogen-like signaling (ANGELS), and osteoporosis: a different perspective on the HRT dilemma. Kidney Int Suppl. 2004 Oct; (91):S41-9.
    View in: PubMed
    Score: 0.010
  24. Lewiecki EM, Bellido T, Bilezikian JP, Brown JP, Farooki A, Kovacs CS, Lee B, Leslie WD, McClung MR, Prasarn ML, Sellmeyer DE. Proceedings of the 2023 Santa Fe Bone Symposium: Progress and Controversies in the Management of Patients with Skeletal Diseases. J Clin Densitom. 2023 Oct-Dec; 26(4):101432.
    View in: PubMed
    Score: 0.010
  25. Bellido T, Ali AA, Plotkin LI, Fu Q, Gubrij I, Roberson PK, Weinstein RS, O'Brien CA, Manolagas SC, Jilka RL. Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism. J Biol Chem. 2003 Dec 12; 278(50):50259-72.
    View in: PubMed
    Score: 0.010
  26. Atkinson EG, Adaway M, Horan DJ, Korff C, Klunk A, Orr AL, Ratz K, Bellido T, Plotkin LI, Robling AG, Bidwell JP. Conditional Loss of Nmp4 in Mesenchymal Stem Progenitor Cells Enhances PTH-Induced Bone Formation. J Bone Miner Res. 2023 01; 38(1):70-85.
    View in: PubMed
    Score: 0.009
  27. Sabol HM, Amorim T, Ashby C, Halladay D, Anderson J, Cregor M, Sweet M, Nookaew I, Kurihara N, Roodman GD, Bellido T, Delgado-Calle J. Notch3 signaling between myeloma cells and osteocytes in the tumor niche promotes tumor growth and bone destruction. Neoplasia. 2022 06; 28:100785.
    View in: PubMed
    Score: 0.009
  28. Plotkin LI, Manolagas SC, Bellido T. Transduction of cell survival signals by connexin-43 hemichannels. J Biol Chem. 2002 Mar 08; 277(10):8648-57.
    View in: PubMed
    Score: 0.008
  29. Sabol HM, Ferrari AJ, Adhikari M, Amorim T, McAndrews K, Anderson J, Vigolo M, Lehal R, Cregor M, Khan S, Cuevas PL, Helms JA, Kurihara N, Srinivasan V, Ebetino FH, Boeckman RK, Roodman GD, Bellido T, Delgado-Calle J. Targeting Notch Inhibitors to the Myeloma Bone Marrow Niche Decreases Tumor Growth and Bone Destruction without Gut Toxicity. Cancer Res. 2021 10 01; 81(19):5102-5114.
    View in: PubMed
    Score: 0.008
  30. Plotkin LI, Bellido T. Bisphosphonate-induced, hemichannel-mediated, anti-apoptosis through the Src/ERK pathway: a gap junction-independent action of connexin43. Cell Commun Adhes. 2001; 8(4-6):377-82.
    View in: PubMed
    Score: 0.008
  31. Chen J, Yuan X, Pilawski I, Liu X, Delgado-Calle J, Bellido T, Turkkahraman H, Helms JA. Molecular Basis for Craniofacial Phenotypes Caused by Sclerostin Deletion. J Dent Res. 2021 03; 100(3):310-317.
    View in: PubMed
    Score: 0.008
  32. Carter CA, Bellido T. Decrease in protein tyrosine phosphorylation is associated with F-actin reorganization by retinoic acid in human endometrial adenocarcinoma (RL95-2) cells. J Cell Physiol. 1999 Mar; 178(3):320-32.
    View in: PubMed
    Score: 0.007
  33. Bellido T, O'Brien CA, Roberson PK, Manolagas SC. Transcriptional activation of the p21(WAF1,CIP1,SDI1) gene by interleukin-6 type cytokines. A prerequisite for their pro-differentiating and anti-apoptotic effects on human osteoblastic cells. J Biol Chem. 1998 Aug 14; 273(33):21137-44.
    View in: PubMed
    Score: 0.007
  34. Bellido T, Borba VZ, Roberson P, Manolagas SC. Activation of the Janus kinase/STAT (signal transducer and activator of transcription) signal transduction pathway by interleukin-6-type cytokines promotes osteoblast differentiation. Endocrinology. 1997 Sep; 138(9):3666-76.
    View in: PubMed
    Score: 0.006
  35. Delgado-Calle J, Anderson J, Cregor MD, Condon KW, Kuhstoss SA, Plotkin LI, Bellido T, Roodman GD. Genetic deletion of Sost or pharmacological inhibition of sclerostin prevent multiple myeloma-induced bone disease without affecting tumor growth. Leukemia. 2017 12; 31(12):2686-2694.
    View in: PubMed
    Score: 0.006
  36. Komaba H, Kaludjerovic J, Hu DZ, Nagano K, Amano K, Ide N, Sato T, Densmore MJ, Hanai JI, Olauson H, Bellido T, Larsson TE, Baron R, Lanske B. Klotho expression in osteocytes regulates bone metabolism and controls bone formation. Kidney Int. 2017 09; 92(3):599-611.
    View in: PubMed
    Score: 0.006
  37. Davis HM, Pacheco-Costa R, Atkinson EG, Brun LR, Gortazar AR, Harris J, Hiasa M, Bolarinwa SA, Yoneda T, Ivan M, Bruzzaniti A, Bellido T, Plotkin LI. Disruption of the Cx43/miR21 pathway leads to osteocyte apoptosis and increased osteoclastogenesis with aging. Aging Cell. 2017 06; 16(3):551-563.
    View in: PubMed
    Score: 0.006
  38. Ayus JC, Bellido T, Negri AL. Hyponatremia and fractures: should hyponatremia be further studied as a potential biochemical risk factor to be included in FRAX algorithms? Osteoporos Int. 2017 05; 28(5):1543-1548.
    View in: PubMed
    Score: 0.006
  39. Bellido T, Stahl N, Farruggella TJ, Borba V, Yancopoulos GD, Manolagas SC. Detection of receptors for interleukin-6, interleukin-11, leukemia inhibitory factor, oncostatin M, and ciliary neurotrophic factor in bone marrow stromal/osteoblastic cells. J Clin Invest. 1996 Jan 15; 97(2):431-7.
    View in: PubMed
    Score: 0.006
  40. Niziolek PJ, MacDonald BT, Kedlaya R, Zhang M, Bellido T, He X, Warman ML, Robling AG. High Bone Mass-Causing Mutant LRP5 Receptors Are Resistant to Endogenous Inhibitors In Vivo. J Bone Miner Res. 2015 Oct; 30(10):1822-30.
    View in: PubMed
    Score: 0.005
  41. Bellido T, Jilka RL, Boyce BF, Girasole G, Broxmeyer H, Dalrymple SA, Murray R, Manolagas SC. Regulation of interleukin-6, osteoclastogenesis, and bone mass by androgens. The role of the androgen receptor. J Clin Invest. 1995 Jun; 95(6):2886-95.
    View in: PubMed
    Score: 0.005
  42. Delgado-Calle J, Bellido T, Roodman GD. Role of osteocytes in multiple myeloma bone disease. Curr Opin Support Palliat Care. 2014 Dec; 8(4):407-13.
    View in: PubMed
    Score: 0.005
  43. Wang L, Zhang H, Rodriguez S, Cao L, Parish J, Mumaw C, Zollman A, Kamoka MM, Mu J, Chen DZ, Srour EF, Chitteti BR, HogenEsch H, Tu X, Bellido TM, Boswell HS, Manshouri T, Verstovsek S, Yoder MC, Kapur R, Cardoso AA, Carlesso N. Notch-dependent repression of miR-155 in the bone marrow niche regulates hematopoiesis in an NF-?B-dependent manner. Cell Stem Cell. 2014 Jul 03; 15(1):51-65.
    View in: PubMed
    Score: 0.005
  44. Artsi H, Cohen-Kfir E, Gurt I, Shahar R, Bajayo A, Kalish N, Bellido TM, Gabet Y, Dresner-Pollak R. The Sirtuin1 activator SRT3025 down-regulates sclerostin and rescues ovariectomy-induced bone loss and biomechanical deterioration in female mice. Endocrinology. 2014 Sep; 155(9):3508-15.
    View in: PubMed
    Score: 0.005
  45. Lezcano V, Bellido T, Plotkin LI, Boland R, Morelli S. Osteoblastic protein tyrosine phosphatases inhibition and connexin 43 phosphorylation by alendronate. Exp Cell Res. 2014 May 15; 324(1):30-9.
    View in: PubMed
    Score: 0.005
  46. Manolagas SC, Yu XP, Girasole G, Bellido T. Vitamin D and the hematolymphopoietic tissue: a 1994 update. Semin Nephrol. 1994 Mar; 14(2):129-43.
    View in: PubMed
    Score: 0.005
  47. Manolagas SC, Jilka RL, Girasole G, Passeri G, Bellido T. Estrogen, cytokines, and the control of osteoclast formation and bone resorption in vitro and in vivo. Osteoporos Int. 1993; 3 Suppl 1:114-6.
    View in: PubMed
    Score: 0.005
  48. Lezcano V, Bellido T, Plotkin LI, Boland R, Morelli S. Role of connexin 43 in the mechanism of action of alendronate: dissociation of anti-apoptotic and proliferative signaling pathways. Arch Biochem Biophys. 2012 Feb 15; 518(2):95-102.
    View in: PubMed
    Score: 0.004
  49. Khosla S, Bellido TM, Drezner MK, Gordon CM, Harris TB, Kiel DP, Kream BE, LeBoff MS, Lian JB, Peterson CA, Rosen CJ, Williams JP, Winer KK, Sherman SS. Forum on aging and skeletal health: summary of the proceedings of an ASBMR workshop. J Bone Miner Res. 2011 Nov; 26(11):2565-78.
    View in: PubMed
    Score: 0.004
  50. Robling AG, Kedlaya R, Ellis SN, Childress PJ, Bidwell JP, Bellido T, Turner CH. Anabolic and catabolic regimens of human parathyroid hormone 1-34 elicit bone- and envelope-specific attenuation of skeletal effects in Sost-deficient mice. Endocrinology. 2011 Aug; 152(8):2963-75.
    View in: PubMed
    Score: 0.004
  51. Turner CH, Warden SJ, Bellido T, Plotkin LI, Kumar N, Jasiuk I, Danzig J, Robling AG. Mechanobiology of the skeleton. Sci Signal. 2009 Apr 28; 2(68):pt3.
    View in: PubMed
    Score: 0.003
  52. Bilezikian JP, Matsumoto T, Bellido T, Khosla S, Martin J, Recker RR, Heaney R, Seeman E, Papapoulos S, Goldring SR. Targeting bone remodeling for the treatment of osteoporosis: summary of the proceedings of an ASBMR workshop. J Bone Miner Res. 2009 Mar; 24(3):373-85.
    View in: PubMed
    Score: 0.003
  53. Kousteni S, Almeida M, Han L, Bellido T, Jilka RL, Manolagas SC. Induction of osteoblast differentiation by selective activation of kinase-mediated actions of the estrogen receptor. Mol Cell Biol. 2007 Feb; 27(4):1516-30.
    View in: PubMed
    Score: 0.003
  54. Manolagas SC, Jilka RL, Kousteni S, Bellido T, Weinstein RS, O'Brien CA, Plotkin L, Han L. Response to Windahl et al. J Clin Invest. 2006 Nov; 116(11):2834.
    View in: PubMed
    Score: 0.003
  55. Vertino AM, Bula CM, Chen JR, Almeida M, Han L, Bellido T, Kousteni S, Norman AW, Manolagas SC. Nongenotropic, anti-apoptotic signaling of 1alpha,25(OH)2-vitamin D3 and analogs through the ligand binding domain of the vitamin D receptor in osteoblasts and osteocytes. Mediation by Src, phosphatidylinositol 3-, and JNK kinases. J Biol Chem. 2005 Apr 08; 280(14):14130-7.
    View in: PubMed
    Score: 0.003
  56. Kousteni S, Han L, Chen JR, Almeida M, Plotkin LI, Bellido T, Manolagas SC. Kinase-mediated regulation of common transcription factors accounts for the bone-protective effects of sex steroids. J Clin Invest. 2003 Jun; 111(11):1651-64.
    View in: PubMed
    Score: 0.002
  57. Kousteni S, Chen JR, Bellido T, Han L, Ali AA, O'Brien CA, Plotkin L, Fu Q, Mancino AT, Wen Y, Vertino AM, Powers CC, Stewart SA, Ebert R, Parfitt AM, Weinstein RS, Jilka RL, Manolagas SC. Reversal of bone loss in mice by nongenotropic signaling of sex steroids. Science. 2002 Oct 25; 298(5594):843-6.
    View in: PubMed
    Score: 0.002
  58. Kousteni S, Bellido T, Plotkin LI, O'Brien CA, Bodenner DL, Han L, Han K, DiGregorio GB, Katzenellenbogen JA, Katzenellenbogen BS, Roberson PK, Weinstein RS, Jilka RL, Manolagas SC. Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell. 2001 Mar 09; 104(5):719-30.
    View in: PubMed
    Score: 0.002
  59. Jilka RL, Weinstein RS, Bellido T, Roberson P, Parfitt AM, Manolagas SC. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest. 1999 Aug; 104(4):439-46.
    View in: PubMed
    Score: 0.002
  60. Jilka RL, Weinstein RS, Bellido T, Parfitt AM, Manolagas SC. Osteoblast programmed cell death (apoptosis): modulation by growth factors and cytokines. J Bone Miner Res. 1998 May; 13(5):793-802.
    View in: PubMed
    Score: 0.002
  61. Yu XP, Bellido T, Manolagas SC. Down-regulation of NF-kappa B protein levels in activated human lymphocytes by 1,25-dihydroxyvitamin D3. Proc Natl Acad Sci U S A. 1995 Nov 21; 92(24):10990-4.
    View in: PubMed
    Score: 0.001
  62. Manolagas SC, Bellido T, Jilka RL. New insights into the cellular, biochemical, and molecular basis of postmenopausal and senile osteoporosis: roles of IL-6 and gp130. Int J Immunopharmacol. 1995 Feb; 17(2):109-16.
    View in: PubMed
    Score: 0.001
  63. Manolagas SC, Bellido T, Jilka RL. Sex steroids, cytokines and the bone marrow: new concepts on the pathogenesis of osteoporosis. Ciba Found Symp. 1995; 191:187-96; discussion 197-202.
    View in: PubMed
    Score: 0.001
  64. Pottratz ST, Bellido T, Mocharla H, Crabb D, Manolagas SC. 17 beta-Estradiol inhibits expression of human interleukin-6 promoter-reporter constructs by a receptor-dependent mechanism. J Clin Invest. 1994 Mar; 93(3):944-50.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.